Medco Taps MolecularMD to Provide BCR-ABL Testing for TKI Inhibitors in CML Patients | GenomeWeb

Originally published June 3.

By Bernadette Toner

Medco Health Solutions has added BCR-ABL testing to its personalized medicine portfolio, marking the tenth such offering under its DNA Direct clinical testing program.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: sequencing technique to uncover plant disease-resistance genes, and more.

In a Science Translational Medicine opinion piece, a Merck executive suggests that universities offer money-back guarantees on their research.

NantKwest's Patrick Soon-Shiong received some $148 million in compensation in 2015.

With sequencing moving toward applications, Illumina CEO Francis deSouza says his company has even more to offer, Fast Company reports.